What is Axio Biosolutions Private?
Founded in 2008 and headquartered in Cambridge, Massachusetts, Axio Biosolutions is a pioneer in the development of ISO 13485-certified medical devices. The company specializes in advanced wound care, utilizing proprietary biopolymer technology to create life-saving products. Its flagship innovation, Axiostat, is a 100% chitosan-based haemostatic dressing designed to control severe haemorrhage within minutes. By facilitating active adhesion to trauma wounds, the product has become a critical asset for defense forces and emergency responders globally. Axio's market position is defined by its ability to bridge the gap between complex material science and practical, frontline medical application, ensuring that its solutions meet the rigorous standards required for emergency trauma management.
How much funding has Axio Biosolutions Private raised?
Axio Biosolutions Private has raised a total of $18.6M across 2 funding rounds:
Series B
$12.6M
Other Financing Round
$6M
Series B (2020): $12.6M with participation from University of California, Chiratae Ventures, Omidyar Network India, and Accel
Other Financing Round (2021): $6M led by Accel, TrueScale Capital, UC Ratan Tata Fund, and Omidyar Network India
Key Investors in Axio Biosolutions Private
Chiratae Ventures
An established Indian technology venture capital firm managing significant assets, focusing on supporting early-stage and portfolio companies through specialized programs like Chiratae Sonic and Spotlight.
Omidyar Network India
A philanthropic investment firm that backs bold entrepreneurs tackling chronic social and economic challenges in India through equity investments and grants in sectors like emerging tech and financial inclusion.
Accel
A global venture capital firm that partners with exceptional teams from inception through all phases of private company growth, providing the expertise needed to scale in competitive markets.
What's next for Axio Biosolutions Private?
With the recent influx of capital, Axio Biosolutions is well-positioned to accelerate its research and development pipeline and broaden its commercial distribution networks. The strategic focus will likely shift toward scaling manufacturing capabilities to meet the rising global demand for its haemostatic dressings while exploring new applications for its biopolymer platform. By maintaining its focus on high-impact medical innovation, the company is poised to strengthen its competitive advantage in the wound care market, potentially diversifying its product portfolio to address a wider range of surgical and trauma-related needs. The continued support from its investor base provides the necessary stability to pursue long-term growth objectives and solidify its status as a leader in medical technology.
See full Axio Biosolutions Private company page
